GSC
NBIX icon

Ground Swell Capital’s Neurocrine Biosciences NBIX Stock Holding History

Ground Swell Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,767
Closed -$496K – 192
2026
Q1 		$496K Buy
+3,767
New +$500K 0.98% 22
2025
Q4 		– Sell
-4,017
Closed -$564K – 148
2025
Q3 		$564K Buy
+4,017
New +$544K 1.23% 22
2021
Q4 		– Sell
-3,846
Closed -$369K – 95
2021
Q3 		$369K Buy
+3,846
New +$363K 1.59% 16
2014
Q3 		$2K Buy
+150
New +$2.24K ﹤0.01% 1916

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Ground Swell Capital's NBIX Position: Q2 2026 in Review

Ground Swell Capital sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 3,767 shares — an estimated $496K sold.

Ground Swell Capital first reported a position in NBIX in Q3 2014 and held it in 4 quarters. The position peaked at $564K in Q3 2025. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Ground Swell Capital reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Ground Swell Capital sold 3,767 Neurocrine Biosciences shares in Q2 2026, an estimated $496K.
  • Ground Swell Capital first reported a position in Neurocrine Biosciences in Q3 2014 and held it in 4 quarters.
  • Ground Swell Capital's Neurocrine Biosciences position peaked at $564K in Q3 2025.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Ground Swell Capital's 13F filing for Q2 2026, filed 5 Aug 2026.